2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Eur Heart J Cardiovasc Imaging
; 23(10): e333-e465, 2022 09 10.
Article
en En
| MEDLINE
| ID: mdl-36017575
Palabras clave
Amyloid light-chain cardiac amyloidosis; Androgen deprivation therapy; Anthracycline; Arrhythmias; Atrial fibrillation; Biomarkers; Cancer; Cancer survivors; Carcinoid syndrome; Cardiac magnetic resonance; Cardiac tumour; Cardio-oncology; Cardiotoxicity; Chemotherapy; Coronary artery disease; Echocardiography; Fluoropyrimidine; Guidelines; Haematopoietic stem cell transplantation; Heart failure; Hormone therapy; Hypertension; Immunotherapy; Ischaemic heart disease; Myocarditis; Pericardial disease; Proteasome inhibitors; Pulmonary hypertension; QTc prolongation; Radiotherapy; Risk stratification; Strain; Thrombosis; Trastuzumab; Valvular heart disease; Vascular endothelial growth factor inhibitors (VEGFi); Venous thromboembolism
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Oncología por Radiación
/
Hematología
/
Neoplasias
/
Antineoplásicos
Tipo de estudio:
Guideline
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Eur Heart J Cardiovasc Imaging
Año:
2022
Tipo del documento:
Article
País de afiliación:
Reino Unido